Will India Cap Medical Device Markups to Protect Care?
The Growing Demand to Rationalise Medical Device Markups
The National Pharmaceutical Pricing Authority recently capped trade margins on non-scheduled anti-cancer medications at 30 percent. Consequently, domestic medtech manufacturers are demanding urgent scrutiny of medical device markups across India. The Association of Indian Medical Device Industry strongly advocates for trade margin rationalisation. However, industry representatives caution that regulatory design will determine overall policy success.
Addressing Inequities Between Importers and Domestic Producers
Earlier pricing interventions created unintentional regulatory gaps between imported and domestic devices. Specifically, regulators previously applied price caps from distributor sale points rather than manufacturer origin. Therefore, the importer sales transaction functioned as a secondary sale point. In contrast, domestic manufacturers faced price limits directly at their primary sale stage. Consequently, landed overseas products ended up with maximum retail prices up to 43 percent higher. AiMeD argues that this system severely disadvantages local manufacturers under Make in India initiatives.
Strategic Recommendations for Medical Device Pricing
To establish fair competition, AiMeD proposed four practical pricing guidelines for health authorities. First, regulators should treat the importer as the first point of sale. Thus, importer margins would fall squarely inside the capped distribution chain. Furthermore, policymakers should apply identical margin disciplines to domestic and imported consumables. The association also recommends launching a pilot framework for high-volume consumables like catheters and IV sets. Finally, authorities must implement a unified national policy designed through transparent stakeholder consultations.
Clinical and Economic Implications for Healthcare Providers
Physicians and hospital administrators face growing pressure regarding opaque procedural supply charges. High hospital markups on basic medical hardware frequently inflate out-of-pocket costs for vulnerable patients. Additionally, state-level pricing restrictions during health emergencies previously caused critical supply shortages. Therefore, structured margin bands protect clinical workflows while preserving healthy supply lines. Transparent device pricing also builds patient trust during complex surgical care.
Frequently Asked Questions
Q1: Why is the industry demanding caps on medical device markups now?
The call follows the NPPA decision to cap margins on anti-cancer drugs at 30 percent. Therefore, medtech associations want similar rationalisation to curb extreme hospital markups on devices.
Q2: How does the current system favor imported medical devices?
Previous regulations placed importer profits outside the capped distribution boundary. Consequently, imported devices often carried retail prices 43 percent higher than identical domestic products.
Q3: Which products should regulators include in an initial pilot?
Industry leaders recommend piloting rationalised margin caps on high-volume consumables. For example, IV sets and catheters offer ideal testing grounds before broader implementation.
References
- After drugs, demand grows for capping Med device markups - ETHealthworld
- AiMeD requests fair treatment for domestic and foreign medical devices in trade margin rationalisation - Pharmabiz.com
- After cancer drugs, medtech firms seek uniform trade margin cap for devices - Business Standard
